Literature DB >> 1959938

Human anti-interleukin 1 alpha antibodies.

M B Hansen1, M Svenson, K Bendtzen.   

Abstract

Autoantibodies to the cytokine interleukin (IL)-1 alpha are frequently found in sera of apparently healthy humans. We have developed a sensitive radioimmunoassay (RIA) and an indirect enzyme-linked immunosorbent assay (ELISA) for the detection of human serum antibodies to IL-1 alpha at concentrations below 10 pmol/l. The RIA is based on coprecipitation of 125I-labelled human recombinant IL-1 alpha (rIL-1 alpha) by rabbit antibodies to human immunoglobulins. The ELISA is based on recovery of added rIL-1 alpha to serum samples and takes advantage of the fact that free human autoantibodies to IL-1 alpha in a dose dependent manner reduce recovery of added rIL-1 alpha. The assays correlate exceedingly well (r = 0.99, P less than 0.001). Their inter- and intraassay coefficients of variation were less than 30% and less than 5% (RIA) and less than 20% and less than 10% (ELISA). Both assays were used to measure the presence of anti-IL-1 alpha antibodies in sera of patients with various autoimmune diseases. Autoantibodies to IL-1 alpha were detectable in up to 75% of these sera, but the frequencies and titers varied considerably between individuals with different diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959938     DOI: 10.1016/0165-2478(91)90102-g

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  Anti-interleukin 1alpha autoantibodies.

Authors:  P Miossec
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

2.  Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.

Authors:  P Aukrust; F Müller; M Svenson; I Nordøy; K Bendtzen; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis.

Authors:  P Jouvenne; F Fossiez; P Garrone; O Djossou; J Banchereau; P Miossec
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

4.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

5.  Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.

Authors:  M B Hansen; M Svenson; K Bendtzen
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

6.  Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis.

Authors:  K Bendtzen; P R Hansen; K Rieneck
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

7.  Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.

Authors:  Roger R Beerli; Monika Bauer; Andrea Fritzer; Lindsey B Rosen; Regula B Buser; Markus Hanner; Melanie Maudrich; Mario Nebenfuehr; Jorge Alejandro Sepulveda Toepfer; Susanne Mangold; Anton Bauer; Steven M Holland; Sarah K Browne; Andreas Meinke
Journal:  MAbs       Date:  2014       Impact factor: 5.857

8.  Increased plasma levels of soluble IL-2R are associated with severe Plasmodium falciparum malaria.

Authors:  P H Jakobsen; S Morris-Jones; T G Theander; L Hviid; M B Hansen; K Bendtzen; R G Ridley; B M Greenwood
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

9.  Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria.

Authors:  P H Jakobsen; V McKay; S D Morris-Jones; W McGuire; M B van Hensbroek; S Meisner; K Bendtzen; I Schousboe; I C Bygbjerg; B M Greenwood
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro.

Authors:  A Rodgaard; B S Thomsen; G Bendixen; K Bendtzen
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.